Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Shouval, Roni ^a,b   Labopin, Myriam ^c,d,e   Unger, Ron ^b   Giebel, Sebastian ^f   Ciceri, Fabio ^g   Schmid, Christoph ^h   Esteve, Jordi ⁱ   Baron, Frederic ^j   Gorin, Norbert Claude ^c   Savani, Bipin ^k   Shimoni, Avichai ^a   Mohty, Mohamad ^c,d,e   Nagler, Arnon ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c HÔPITAL SAINT ANTOINE   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^f INSTITUTE OF ONCOLOGY   (Poland)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j UNIVERSITY OF LIÈGE   (Belgium)

^k VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LEUKEMIA; ADULT; ALGORITHM; ARTICLE; CANCER STAGING; COMPUTER MODEL; COMPUTER PREDICTION; DATA MINING; FEMALE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA REMISSION; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL BLOOD STEM CELL; PREDICTION; PREVALENCE; RECEIVER OPERATING CHARACTERISTIC; REDUCED INTENSITY CONDITIONING; SAMPLE SIZE; T CELL DEPLETION; TRANSPLANTATION RELATED MORTALITY; UNRELATED DONORS; ADVERSE EFFECTS; ALLOTRANSPLANTATION; AREA UNDER THE CURVE; COMPUTER SIMULATION; EUROPE; INFORMATION PROCESSING; LEUKEMIA, MYELOID, ACUTE; MEDICAL SOCIETY; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE; RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; TRANSPLANTATION CONDITIONING;

ADULT; ALGORITHMS; AREA UNDER CURVE; COMPUTER SIMULATION; DATA COLLECTION; DATA MINING; EUROPE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MACHINE LEARNING; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84961285352     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150637     Document Type: Article

References (35)

1. Copelan EA. Hematopoietic stem-cell transplantation. The New England journal of medicine. 2006; 354 (17):1813-26. PMID: 16641398.
2. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998; 352(9134):1087-92. PMID: 9798583.
3. Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, De Witte T, et al. Risk Score for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation A Retrospective Analysis. Cancer. 2009; 115(20):4715-26. doi: 10.1002/cncr.24531 WOS:000270740900011. PMID: 19642176
4. Barba P, Martino R, Perez-Simon JA, Fernandez-Aviles F, Castillo N, Pinana JL, et al. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014; 20(1):66-72. doi: 10.1016/j.bbmt.2013.10.011 PMID: 24141006.
5. Nakaya A, Mori T, Tanaka M, Tomita N, Nakaseko C, Yano S, et al. Does the Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) Predict Transplantation Outcomes? A Prospective Multicenter Validation Study of the Kanto Study Group for Cell Therapy. Biol Blood Marrow Transplant. 2014; 20(10):1553-9. doi: 10.1016/j.bbmt.2014.06.005 PMID: 25034961.
6. Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Annals of internal medicine. 2006; 144(6):407-14. PMID: 16549853.
7. Raimondi R, Tosetto A, Oneto R, Cavazzina R, Rodeghiero F, Bacigalupo A, et al. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: A prospective, multicenter GITMO study. Blood. 2012; 120(6):1327-33. PMID: 22740454. doi: 10.1182/blood-2012-03-414573
8. Versluis J, Labopin M, Niederwieser D, Socie G, Schlenk RF, Milpied N, et al. Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. Leukemia. 2015; 29(1):51-7. doi: 10.1038/leu.2014.164 WOS:000347673700006. PMID: 24913728
9. Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F, et al. Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. Journal of Clinical Oncology. 2015:JCO. 2014.59. 1339.
10. Breiman L. Statistical modeling: The two cultures (with comments and a rejoinder by the author). Statistical Science. 2001; 16(3):199-231.
11. Shouval R, Bondi O, Mishan H, Shimoni A, Unger R, Nagler A. Application of machine learning algorithms for clinical predictive modeling: A data-mining approach in SCT. Bone marrow transplantation. 2014; 49(3):332-7. doi: 10.1038/bmt.2013.146 PMID: 24096823
12. Shouval R, Nagler A, Labopin M, Unger R. Interpretable Boosted Decision Trees for Prediction of Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation. J Data Mining Genomics Proteomics. 2015; 6(4):2. 13./MED-AB Forms Manual: Http://www.ebmt.org/Contents/Data-Management/Registrystructure/MEDABdatacollectionforms/Documents/MED-ABFormsManual.pdf.
13. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD Statement. BMC medicine. 2015; 13(1):1.
14. Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and elaboration. Annals of internal medicine. 2015; 162(1):W1-W73. doi: 10.7326/M14-0698 PMID: 25560730
15. Breiman L. Random Forests. Machine Learning. 2001; 45(1):5-32.
16. Freund Y, Mason L, editors. The alternating decision tree learning algorithm. ICML; 1999.
17. Freund Y, Schapire R, Abe N. A short introduction to boosting. Journal-Japanese Society For Artificial Intelligence. 1999; 14(771-780):1612.
18. Han J, Kamber M, Pei J. Data Mining: Concepts and Techniques. 3rd ed: Morgan Kaufmann; 2012.
19. Hastie T, Tibshirani R, Friedman J, Hastie T, Friedman J, Tibshirani R. The elements of statistical learning: Springer; 2009.
20. Krogh A. What are artificial neural networks? Nature biotechnology. 2008; 26(2):195-7. PMID: 18259176. doi: 10.1038/nbt1386
21. Shouval R, Bondi O, Mishan H, Shimoni A, Unger R, Nagler A. Application of machine learning algorithms for clinical predictive modeling: A data-mining approach in SCT. Bone marrow transplantation. 2014; 49(3):332-7. doi: 10.1038/bmt.2013.146 PMID: 24096823.
22. Hall MA, Holmes G. Benchmarking attribute selection techniques for discrete class data mining. Knowledge and Data Engineering, IEEE Transactions on. 2003; 15(6):1437-47.
23. Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhauser M, Juliusson G, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: An integrated-risk adapted approach. Nature reviews Clinical oncology. 2012; 9(10):579-90. doi: 10.1038/nrclinonc.2012.150 PMID: 22949046.
24. Cornelissen JJ, Van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom? Blood. 2007; 109(9):3658-66. doi: 10.1182/blood-2006-06-025627 PMID: 17213292.
25. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. Jama. 2009; 301(22):2349-61. PMID: 19509382. doi: 10.1001/jama.2009. 813
26. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: A metaanalysis. Cancer. 2005; 103(8):1652-8. doi: 10.1002/cncr.20945 PMID: 15742336.
27. Socié G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. New England Journal of Medicine. 1999; 341(1):14-21. PMID: 10387937
28. Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, De Witte T, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: A retrospective analysis. Cancer. 2009; 115 (20):4715-26. PMID: 19642176. doi: 10.1002/cncr.24531
29. Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shahjahan M, Maloney DG, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: Combined FHCRC and MDACC experiences. Blood. 2007; 110(13):4606-13. doi: 10.1182/blood-2007-06-096966 PMID: 17873123; PubMed Central PMCID: PMCPMC2234788.
30. Teixeira GM, Bittencourt H, De Macedo AV, Martinho GH, Colosimo EA, Rezende SM. Assessing the Influence of Different Comorbidities Indexes on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in a Developing Country. PloS one. 2015; 10(9):e0137390. doi: 10.1371/journal.pone. 0137390 PMID: 26394228.
31. Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, et al. Comorbidity-age index: A clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014; 32(29):3249-56. doi: 10.1200/JCO.2013.53.8157 PMID: 25154831; PubMed Central PMCID: PMCPMC4178523.
32. Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. The New England journal of medicine. 2015; 373(12):1136-52. doi: 10.1056/NEJMra1406184 PMID: 26376137.
33. Lauer MS, D'Agostino RB Sr., The randomized registry trial-the next disruptive technology in clinical research? The New England journal of medicine. 2013; 369(17):1579-81. PMID: 23991657. doi: 10. 1056/NEJMp1310102
34. Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS. Random survival forests. The Annals of Applied Statistics. 2008:841-60.
35. Hsich E, Gorodeski EZ, Blackstone EH, Ishwaran H, Lauer MS. Identifying important risk factors for survival in patient with systolic heart failure using random survival forests. Circulation: Cardiovascular Quality and Outcomes. 2011; 4(1):39-45.